Charles S. Carignan, MD

Dr. Charles S. Carignan (Chuck) is the Executive Chairman of Cairdac, developer of a novel leadless pacemaker; Chairman of SamanTree Medical, the leader in intraoperative tumor margin assessment; Chairman of Anaconda Biomed, developer of a next generation catheter for the treatment of embolic stroke; and, is a Director of Biothea and Prothea. He also serves as the acting CMO to Surge Therapeutics, a developer of novel, sustained release immunologics for the treatment of cancer. Chuck is the prior CEO of SoniVie (sold to Boston Scientific), and previously served as the Executive Chair and CEO of Rex Bionics, as the President and CEO of BionX Medical Technology (sold to Ottobock), founding President and CEO of NinePoint Medical, Executive Vice President and Chief Medical Officer of Novasys Medical, Inc. (sold to Roper), Chief Medical Officer at Boston Scientific, and Vice President of clinical research and medical affairs at Conceptus (sold to Bayer). He has served healthcare worldwide participating on committees of the U.S. Food and Drug Administration, Centers for Medicare & Medicaid Services, the World Health Organization, the United Nations, and the U.S. Agency for International Development. He received a BA from Yale University and an MD from the College of Physicians and Surgeons, Columbia University. He trained in general surgery at Columbia-Presbyterian Medical Center.